Streetbeat News

UNCY

Unicycive Therapeutics, Inc.

https://www.unicycive.com

Industry

Biotechnology

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Open

0.75

Mkt cap

74M

Volume

625K

High

0.76

P/E Ratio

-1.55

52-wk high

1.82

Low

0.70

Div yield

N/A

52-wk low

0.20

Unicycive Therapeutics, a clinical-stage biotech company, will participate in two investor conferences in December, including a fireside chat at the Piper Sandler 36th Annual Healthcare Conference.

Portfolio Pulse from

November 21, 2024 | 12:15 pm

Unicycive Therapeutics, Inc. announced its Q3 2024 financial results and provided a business update. The FDA accepted the NDA for OLC with a PDUFA date set for June 28, 2025. The company is planning for a 2025 commercial launch and completed a Phase 1 trial for UNI-494.

Portfolio Pulse from

November 13, 2024 | 12:30 pm

Unicycive Therapeutics announced that the FDA has accepted their NDA for Oxylanthanum Carbonate, a treatment for hyperphosphatemia in dialysis patients, with a PDUFA date set for June 28, 2025. The company is preparing for a commercial launch in 2025.

Portfolio Pulse from

November 11, 2024 | 12:15 pm

Unicycive Therapeutics shares rose following the announcement of poster presentations for Oxylanthanum Carbonate and UNI-494 at the American Society of Nephrology Kidney Week 2024.